Active, not recruitingNo phase
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- France22 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 192 people enrolled
- Started
- 17 Jun 2024
- Expected to end
- 30 Jun 2027
- Type of study
- Observational
- Treatments tested
- secukinumab
- Record updated
- 29 January 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male and female patients ≥ 18 years old,
- Patients who do not object to participation in the study,
- Diagnosis of HS clinically confirmed,
- Initiation of secukinumab treatment for HS in compliance with the summary of product characteristics,
- The physician's decision to initiate secukinumab has been taken according to his/her own practice and regardless of study participation
Who cannot take part
- Patients with any medical or psychological condition which, in the physician's opinion, may prevent participation in the study,
- Patients participating in a clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.
The group in the trial
- secukinumab
Patients prescribed with secukinumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation: a French Multicentric Prospective Observational Study
- Record updated
- 29 January 2026